Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Biochim Biophys Acta. 2014 Mar 12;1841(6):880–887. doi: 10.1016/j.bbalip.2014.03.001

Figure 5.

Figure 5

Rapamycin treatment had no effect on Acsl activity or the altered fuel uptake, but caused glucose intolerance. A) Acsl specific activity in ventricles from control and Acsl1H−/− mice treated with vehicle (Veh) or rapamycin (Rapa). B) Uptake of 2-bromo[1-14C]palmitate into the ventricles of control and Acsl1H−/− mice. C) 2-Deoxy[1-14C]glucose uptake into the ventricles of control and Acsl1H−/− mice treated with vehicle or rapamycin. n = 3–5 per group. D) mRNA abundance of Glut1 and Glut4 in ventricles from control and Acsl1H−/− mice treated with vehicle (Veh) or rapamycin (Rapa). The values show means plus SEMs (error bars); *, p<.005 compared with littermate controls and #, p<.03 compared with vehicle control. n = 5–6 per group. E) Plasma glucose at intervals after i.p. glucose (2.5 g/kg body wt) in control and Acsl1H−/− mice treated with vehicle or rapamycin. n = 5 per group.